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Abstract
Poly(ADP-ribose) polymerase-1 (PARP-1) and nuclear factor kappaB (NF-kappaB) have both been
demonstrated to play a pathophysiological role in a number of inflammatory disorders. We recently
presented evidence that PARP-1 can act as a promoter-specific coactivator of NF-kappaB in vivo
independent of its enzymatic activity. PARP-1 directly interacts with p300 and both subunits of
NF-kappaB (p65 and p50) and synergistically coactivates NF-kappaB-dependent transcription. Here we
show that PARP-1 is acetylated in vivo at specific lysine residues by p300/CREB-binding protein upon
stimulation. Furthermore, acetylation of PARP-1 at these residues is required for the interaction of
PARP-1 with p50 and synergistic coactivation of NF-kappaB by p300 and the Mediator complex in
response to inflammatory stimuli. PARP-1 physically interacts with the Mediator. Interestingly, PARP-1
interacts in vivo with histone deacetylases (HDACs) 1-3 but not with HDACs 4-6 and might be
deacetylated in vivo by HDACs 1-3. Thus, acetylation of PARP-1 by p300/CREB-binding protein plays
an important regulatory role in NF-kappaB-dependent gene activation by enhancing its functional
interaction with p300 and the Mediator complex.
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Poly(ADP-ribose) polymerase-1 (PARP-1) and nuclear factor B
(NF-B) have both been demonstrated to play a pathophysiological
role in a number of inflammatory disorders.We recently presented
evidence that PARP-1 can act as a promoter-specific coactivator of
NF-B in vivo independent of its enzymatic activity. PARP-1
directly interacts with p300 and both subunits of NF-B (p65 and
p50) and synergistically coactivates NF-B-dependent transcrip-
tion. Here we show that PARP-1 is acetylated in vivo at specific
lysine residues by p300/CREB-binding protein upon stimulation.
Furthermore, acetylationofPARP-1 at these residues is required for
the interaction of PARP-1 with p50 and synergistic coactivation of
NF-Bby p300 and theMediator complex in response to inflamma-
tory stimuli. PARP-1 physically interacts with the Mediator. Inter-
estingly, PARP-1 interacts in vivo with histone deacetylases
(HDACs) 1–3 but not with HDACs 4–6 and might be deacety-
lated in vivo by HDACs 1–3. Thus, acetylation of PARP-1 by
p300/CREB-binding protein plays an important regulatory role
in NF-B-dependent gene activation by enhancing its functional
interaction with p300 and the Mediator complex.
Nuclear factor B (NF-B) is a widely expressed transcription factor
of particular importance to the regulation of cells of the immune system
(1). NF-B encompasses a family of inducible transcription factors
including RelA/p65, RelB, c-Rel, p50, and p52 (1). These proteins share
a conserved 300-amino acid region within their amino termini, desig-
nated Rel-homology domain (RHD). This domain is responsible for
dimerization, nuclear translocation, DNA binding, and interaction with
heterologous transcription factors (1). NF-B is composed of homo- or
heterodimers with a range of DNA binding and activation potentials.
The most abundant and best-studied form of NF-B in cells is a het-
erodimer consisting of the two subunits, p50 (NF-B1) and p65 (RelA).
NF-B plays a key role in the regulation of many genes involved in
mammalian immune and inflammatory responses, apoptosis, cell pro-
liferation, and differentiation (1, 2). NF-B has additionally been asso-
ciated with neurodegenerative processes and cancer (3, 4). In unstimu-
lated cells, NF-B is sequestered in the cytoplasm as an inactive
transcription factor complex by its physical association with one of sev-
eral inhibitors ofNF-B (IBs)2 (5). Treatment of cells with extracellular
stimuli including cytokines, bacterial lipopolysaccharides (LPS), phor-
bol esters, or potent oxidants leads to rapid phosphorylation of IB,
which results in ubiquitination of IB and subsequent degradation by
the 26 S proteasome (4, 5). Dissociation of NF-B unmasks the nuclear
localization sequences of p65 and p50 subunits, which leads to nuclear
translocation and binding of NF-B to specific B consensus sequences
in the chromatin and activation of specific subsets of genes (3).
NF-B-dependent gene expression requires growing families of tran-
scriptional coactivators (6, 7). The two key coactivators of NF-B, his-
tone acetyltransferases p300 and its homolog, the cAMP-response ele-
ment-binding protein (CREB)-binding protein (CBP), directly associate
with the NF-B subunits p50 and p65 (8–10). These coactivators are
thought to promote the rapid formation of the pre-initiation and re-ini-
tiation complexes by bridging the sequence-specific activators (like
NF-B) to the basal transcription machinery, thereby facilitating mul-
tiple rounds of transcription (11). Additionally, the histone acetyltrans-
ferases p300 and CBP can modify the amino-terminal tails of nucleoso-
mal histones, thereby altering the local chromatin structure (12–14).
Although the recruitment of p300 or CBP to NF-B-dependent enhan-
ceosomes is required for synergistic activation, tethering p300/CBP
alone to the promoter through NF-B is not sufficient for full activity of
NF-B in the context of chromatin. Several reports indicated that the
combined actions and interactions of distinct transcriptional coactiva-
tor complexes and cofactors seem to be attributable to the strong tran-
scriptional activity of NF-B, depending on the stimuli and the cell type
(6, 8, 15, 16).
Poly(ADP-ribose) poly-merase-1 (PARP-1) is a nuclear chromatin-
associated protein and belongs to a large family of enzymes that can
synthesize polymers of ADP-ribose units by using -nicotinamide ade-
nine dinucleotide (NAD) as substrate (17). PARP-1 and NF-B have
both been suggested to play a pathophysiological role in a number of
inflammatory disorders (17). Several studies showed that PARP-1(/)
mice were protected against myocardial infarction, streptozotocin-in-
duced diabetes, LPS-induced septic shock, zymosan-induced vascular
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failure, a non-septic model of multiple organ dysfunction as well as
collagen-induced arthritis. This indicates that PARP-1 has a vital role in
inflammatory disorders (17). PARP-1 has been suggested to act as a
promoter-specific coactivator of NF-B in these inflammatory disor-
ders (18). Indeed, up-regulation of subsets of inflammatory mediators
such as TNF, IFN, and iNOS was shown to be impaired in PARP-
1(/) mice upon treatment with LPS, zymosan, or streptozotocin (17,
19). We recently presented evidence that PARP-1 can act as a coactiva-
tor of NF-B in vivo (18). Neither the nuclear translocation nor the
DNA binding ability of NF-B was affected in PARP-1(/) cells (18).
However, PARP-1 directly interacted with both subunits of NF-B (p65
and p50) in vitro and in vivo (18, 20). Remarkably, the enzymatic activity
of PARP-1 was not required for full activation of NF-B in response to
various stimuli in vivo (20). In addition, PARP-1 directly interacted with
p300 and synergistically coactivated NF-B-dependent transcription
(8). Tulin and Spradling (21) recently found that Drosophila mutants
lacking normal PARP-1 levels display immune defects similar to mice
lacking the NF-B subunit p50. Their results imply that the role of
PARP-1 in NF-B-dependent gene expression during immune
responses has been conserved during evolution.
Because NF-B-dependent gene expression requires post-transla-
tional modifications (22), we decided to test whether the coactivator
activity of PARP-1 might also be regulated by post-translational modi-
fications. We show here that PARP-1-dependent gene expression not
only requires the enzymatic activity of p300/CBP but also that PARP-1
itself is acetylated in vivo in response to inflammatory stimuli. Acetyla-
tion sites weremapped in vitro and in vivo to Lys-498, Lys-505, Lys-508,
Lys-521, and Lys-524. Furthermore, acetylation of PARP-1 at these
lysines is required for the interaction with p50 and the transcriptional
activation of NF-B in response to inflammatory stimuli. Interestingly,
the synergistic coactivation of PARP-1, p300, and also the Mediator
complex was dependent on acetylation of PARP-1. Moreover, PARP-1
interacted with and is potentially deacetylated in vivo by class I HDACs.
PARP-1-dependent transcriptional activation of NF-B was negatively
regulated by HDACs 1–3 in vivo. Together, these results support the
hypothesis that acetylation of PARP-1 is important for its role as tran-
scriptional coactivator and that the different physiological functions of
PARP-1 might be in general regulated by post-translational modifica-
tions in a stimulus-dependent manner.
MATERIALS ANDMETHODS
Reagents—Recombinant TNF was obtained from R&D Systems.
Phorbol esters andmouse interferon-was purchased from Sigma. LPS
(Escherichia coli, O26:B6) prepared by phenol extractionwas purchased
from Sigma and prepared as dispersed sonicate in endotoxin-free water
before diluting to a final concentration in supplemented media. Nonfat
dry milk was obtained fromMigros (Switzerland). Nitrocellulose mem-
branes were purchased fromOsmonics Inc. Tosyl-activated Dynabeads
were purchased from Dynal Biotech GmbH.
Plasmids—GST-PARP-1 and GST-p50 full-length expression vec-
tors, CMV-PARP-1, and CMV-p300 expression vectors were described
in Hassa et al. (8) and Covic et al. (16). The CMV expression vectors for
the different Mediator subunits were generated by PCR or were a gen-
erous gift from Dr. L. Freedman (Merck Research Laboratories, West
Point, NY). The CMV expression vectors for Myc-tagged HDACs 1–3
were created by PCR. The CMV expression vectors for FLAG or hem-
agglutinin-tagged HDAC 4–6 were kind gifts from Dr. S. L. Schreiber
(Harvard University, Cambridge, MA). The expression vectors for
CDK8/cyclin C and subunits of TFIID and TFIIF were kind gifts from
Dr. M. Otsuka (University of Tokyo, Japan), Dr. Z. F. Burton (Michigan
StateUniversity, East Lansing,MI), andDr.G.Napolitano (University of
Naples “Frederico II,” Naples, Italy). NF-B-dependent luciferase
reporter constructs for MIP-2 (MIP-2 (531/wt and MIP-2 (-531/
mutB)-Luc) and iNOS (iNOS (1485/31wt)-Luc and iNOS(1485/
31-mutB)-Luc) were generous gifts from Dr. H.-J. Kwon, (Yonsei
University, Seoul, Korea) and Dr. M. A. Perrella (Harvard School of
Public Health, Boston, MA) and are described in Perrella et al. (23) and
Kim et al. (24). pphRSV-nt--galactosidase is described in Hassa et al.
(20). The baculovirus for CDK8 and cyclin C was a generous gift from
Dr. R. Pinhero (University of Guelph, Ontario, Canada) (25). The bacu-
lovirus for human p300 and mouse CBP was a generous gift from Dr.
W. L. Kraus (Cornell University, New York) and Dr. D. Thanos (Insti-
tute of Molecular Biology and Genetics, Alexander Fleming Biomedical
Sciences Research Center, Athens, Greece). The baculovirus for
PARP-1 full-length and different domains were created by PCR using
the PAK-8/9 system (BD Biosciences). GST-fusion expression vectors
for different domains of PARP-1 were created by PCR. The PARP-1
mutant constructs were obtained by site-directedmutagenesis and con-
firmed by sequencing.
Mice Breeding Conditions, Cell Culture, and Transient Trans-
fections—129S/EV-PARP-1(/) and 129S/EV-PARP-1(/) mice
were bred under specified pathogen-free conditions. The initial 129S/
EV-PARP-1(/) and 129S/EV-PARP-1(/) mice breeding pairs
were a kind gift from Dr. Z. Q. Wang (26) (International Agency for
Research on Cancer, Lyon, France). Primary macrophage cells were
isolated from fresh littermates of 129S/EV-PARP-1(/) and 129S/
EV-PARP-1(/) mice (20, 26) according to an isolation procedure
described in Petrilli et al. (19), and human monocyte/macrophage-like
THP-1 cells and Jurkat-T cells were grown in Hepes-buffered RPMI-
Glutamax-I (Invitrogen) containing 10% fetal calf serum U. S.-certified
(Invitrogen) and supplemented with 50 units/ml penicillin, 50 g/ml
streptomycin (Invitrogen), 1 mM sodium pyruvate, 0.05 mM -mercap-
toethanol, and minimum Eagle’s medium-nonessential amino acids.
Primary mouse fibroblast cells were grown in Hepes-buffered Dulbec-
co’s modified Eagle’s medium-Glutamax-I (Invitrogen) containing 4.5
g/liter glucose, 10% fetal calf serumU. S.-certified (Invitrogen) and sup-
plemented with 50 units/ml penicillin, 50 g/ml streptomycin (Invitro-
gen), 1 mM sodium pyruvate, 0.05 mM -mercaptoethanol, and mini-
mum Eagle’s medium-nonessential amino acids. HEK293 cells were
grown in Hepes-buffered Dulbecco’s modified Eagle’s medium-Glu-
tamax-I (Invitrogen) containing 4.5 g/liter glucose and 10% fetal calf
serum U. S.-certified (Invitrogen) and supplemented with 50 units/ml
penicillin, 50 g/ml streptomycin (Invitrogen), and minimum Eagle’s
medium-nonessential amino acids. For luciferase reporter assays, cells
were grown in 24- or 48-well dishes. Cells were transfected using cal-
cium phosphate or polyethyleneimine procedures (as described in Refs.
27–30) except that primary cells were grown for 12 h in RPMI medium
containing 2% fetal calf serum before stimulation with TNF or LPS/
IFN. The amount of DNA indicated in the figure legends was calcu-
lated for 10 ml of medium. Total amounts of DNA and equal molar
ratios of promoters were kept constant in all set-ups by using empty
vectors. For primary cells only cell passages 1–4 were used for transfec-
tion experiments. Because of differences in transfection efficiencies, an
expression plasmid of -galactosidase (pph-RSV-nt--Gal) was
co-transfected as a transfection efficiency control, and luciferase activ-
ities were normalized based on -galactosidase activity. Luciferase
activity wasmeasured as previously described in Hottiger et al. (27). For
further experimental procedures see the supplemental material.
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FIGURE 1. PARP-1 is acetylated upon stimulation in vivo and requires the enzymatic activity of p300 for full NF-B-dependent transcriptional activity. A, primary PARP-
1(/) or PARP-1(/) macrophages were treated with LPS (0.1 g/ml) as indicated, and the expression of hypoxanthine-guanine phosphoribosyltransferase (HPRT), glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH), andNF-B-dependent genes KC,MIP-2, iNOS, IB and interleukin-6 (IL-6) was assessed by reverse transcription-PCR. B, equal amounts
of total cell extracts fromprimary PARP-1(/) and PARP-1(/) lung fibroblasts or primary PARP-1(/) and PARP-1(/) macrophageswere resolved by SDS-PAGE followed by
immunoblot analysis using anti-p300, anti-PARP-1, anti-PCAF, or anti--tubulin antibodies. C andD, primary PARP-1(/) macrophageswere cotransfectedwith RSV-nt--Gal (300
ng), expression vectors for PARP-1 (2g), andwild type (WT) or an enzymaticmutant (Mut) of p300 (2g) alongwith a luciferase reporter under the control of the endogenousMIP-2
(1g)or iNOS (3g)promoters; cellswere subsequently treated for 4hwithTNF (10ng/ml) or LPS/IFN (0.05g/ml/100units) in the simultaneouspresenceor absenceof lowdoses
of deacetylase inhibitors (10 nM TSA/200MNAM). Cellswere harvested 24h after transfection, andNF-B-dependent gene expressionwas determined. The indicated activationwas
determined by the ratio of the relative luciferase activitymeasured for the promoters containingwild type B sites (black bars) or mutB sites (white bars) after stimulation. The ratio
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RESULTS
PARP-1 Requires the Enzymatic Activity of p300 for Full NF-B-
dependent Transcriptional Activity and Is Acetylated in Vivo by p300/
CBP upon Stimulation—Because the coactivator activity of PARP-1 for
NF-B-dependent gene expression is dependent on the stimuli and cell
type (17), we first tested which NF-B-dependent genes are impaired in
freshly isolated primary PARP-1(/) macrophages. Primary PARP-
1(/) or PARP-1(/) macrophages were treated with LPS as indi-
cated, and the expression of NF-B-dependent genes was assessed by
reverse transcription-PCR (Fig. 1A). The experiments revealed that
LPS-induced levels of KC, MIP-2, and iNOS were impaired in PARP-
1(/) cells (Fig. 1A). The expression of IB and interleukin-6 (IL-6)
was not reduced (Fig. 1A), indicating that only a subset of NF-B-de-
pendent genes requires PARP-1 for gene induction in these cells. Similar
results were obtained when cells were stimulated with TNF (data not
shown). To confirm that the expression levels of histone acetyltrans-
ferases are not reduced in primary PARP-1 (/) cells, we tested the
protein levels of p300 and PCAF by immunoblot analysis using anti-
PARP-1, anti-p300, or anti-PCAF antibodies. The endogenous protein
levels of p300 and PCAF were not impaired in freshly isolated primary
PARP-1(/) lung fibroblast or macrophage cells (Fig. 1B).
PARP-1 and p300/CBP were shown to form a complex and function
synergistically to enhance NF-B-mediated gene expression (8). To test
whether the synergistic coactivation of NF-B-mediated transactiva-
tion by PARP-1 and p300/CBP might require the enzymatic activity of
p300/CBP, we transfected PARP-1(/) cells with expression vectors
for PARP-1 and wild type or an enzymatic mutant of p300 along with a
luciferase reporter under the control of the endogenousMIP-2 or iNOS
promoters, shown to be PARP-1-dependent. Cells were subsequently
treated with TNF or LPS/IFN in the simultaneous presence or
absence of low doses of deacetylase inhibitors (TSA and nicotinamide
(NAM)) (Fig. 1, C andD). Coexpression of wild type p300 with PARP-1
in PARP-1(/) cells resulted in a highly synergistic enhancement of
transcription regulated from both MIP-2 and iNOS promoters upon
stimulation (Fig. 1, C andD). However, the cooperativity between p300
and PARP-1 was severely impaired when an enzymatic mutant of p300
FIGURE 1—continued
obtained for untreated cells was arbitrarily set to 1. Error bars indicate S.E. of three independent experiments. E and F, primary PARP-1(/) and PARP-1(/) macrophages were
repeatedly transfected with scrambled- or p300-siRNA targeting vector DNA (30 g) as indicated and then transfected and treated as indicated and described in D. The indicated
activation was determined as described in D. G, equal amounts of total cell extracts from primary macrophages repeatedly transfected with scrambled- or p300-siRNA targeting
vector DNA (30 g) as indicated were resolved by SDS-PAGE followed by immunoblot analysis using anti-p300 or anti- -tubulin antibodies. H, THP-1 or Jurkat-T cells were treated
as indicated with LPS (0.2g/ml) or phorbol ester (10 nM) and simultaneously with or without deacetylase inhibitors (100 nM TSA/400M NAM) for 30min. PARP-1 was immunopre-
cipitated (IP) under high salt conditions from nuclear extracts, and the presence of acetylated forms of PARP-1 was subsequently tested by immunoblot analysis using anti-AcK or
anti-PARP-1 antibodies. PMA, phorbol 12-myristate 13-acetate. I, left panel, 293 cells were repeatedly transfectedwith scrambled-, p300-, or CBP-siRNA targeting vector DNA (30g)
and treated as indicated. PARP-1was immunoprecipitated under high salt conditions fromnuclear extracts, and the presence of acetylated forms of PARP-1was subsequently tested
by immunoblot analysis using anti-AcK or anti-PARP-1 antibodies. Right panel, equal amounts of total cell extracts from 293 cells repeatedly transfected with scrambled- or
p300-siRNA targeting vector DNA (30 g) as indicated were resolved by SDS-PAGE followed by immunoblot analysis using anti-p300 or anti- -tubulin antibodies.
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was coexpressed. The most striking differences between wild type and
the enzymatic mutant of p300 were observed in the presence of low
doses of deacetylase inhibitors (Fig. 1, C and D). The same transfection
experiments with a reporter gene under the control of mutated B sites
revealed that the observed cooperative effect of p300 and PARP-1 was
mainly NF-B-specific (Fig. 1, C and D). To further confirm these
FIGURE 2.PARP-1 is acetylated in vitroand in vivoat Lys-498, Lys-505, Lys-508, Lys-521, andLys-524byp300/CBPuponstimulation.A, recombinantpurified full-lengthPARP-1was
incubatedwith recombinant purified full-length p300 or CBP in the presence of radioactive labeled acetyl-CoA and resolved by SDS-PAGE followed by autoradiography. B, baculo-purified
PARP-1 fragments corresponding to aminoacids (aa) 1–214, 215–372, 373–525, 525–656, or 657–1014were incubatedwith recombinant purified full-lengthp300orCBP in thepresenceof
radioactive labeled acetyl-CoA and resolved by SDS-PAGE followed by autoradiography. C, recombinant purified full-length PARP-1 wild type and two mutant forms of PARP-1; mutKTR
(K498R/K521R/K524R)andmutKQR(K498R/K505R/K508R/K521R/K524R)were incubatedwith recombinantpurified full-lengthp300orCBP in thepresenceof radioactive labeledacetyl-CoA
and resolved by SDS-PAGE followed by autoradiography.D, Myc-tagged PARP-1wild type (WT) ormutantmutKQRwere overexpressed in 293 cells and treated as indicatedwith TNF (10
ng/ml) and/or deacetylase inhibitors (100 nM TSA/400MNAM) for 30min. Myc-tagged PARP-1 wild type ormutantmutKQRwas then immunoprecipitated (IP) under high salt conditions
fromnuclear extracts of 293 cells, and thepresenceof acetylated formsof PARP-1was subsequently testedby immunoblot analysis (IB) usinganti-AcKor anti-PARP-1 antibodies. E, the same
experimentswere repeated in the presence of increasing amounts of overexpressed p300. Immunoblot of p300 input is shown in the upper panels
PARP-1 Is Acetylated by p300/CBP
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results, the same experiments were repeated in the presence of different
p300-siRNA targeting vectors (Fig. 1, E and F). These experiments
revealed that the presence of endogenous p300 is required for PARP-1-
dependent coactivation of NF-B-dependent gene expression (Fig. 1, E
and F). Together these results indicate that the enzymatic activity of
p300/CBP is required for NF-B-dependent transactivation of extra-
chromosomal templates upon treatment with inflammatory stimuli.
p300 and CBP are known to modify a variety of proteins, such as
histones and transcription factors (31). To investigate whether endog-
enous PARP-1 itselfmight be acetylated by p300/CBP in vivo, we immu-
noprecipitated endogenous PARP-1 under high salt conditions from
nuclear extracts of THP-1 or Jurkat-T cells upon treatment with the
indicated stimuli (LPS or TNF) in the simultaneous presence or
absence of deacetylase inhibitors (Fig. 1H, left and right panels). Possible
acetylation of PARP-1 was analyzed by immunoblot analysis using an
anti-AcK antibody. Endogenous PARP-1 was acetylated in vivo only in
the presence of deacetylase inhibitors upon stimulation of these cells
(Fig. 1H, left and right panels). Next we tested whether the observed
acetylation of PARP-1 is dependent on p300/CBP. 293 cells were
cotransfected with a control-siRNA vector and/or different siRNA tar-
geting vectors for p300 or CBP. Endogenous PARP-1 was immunopre-
cipitated under high salt conditions from nuclear extracts of 293 cells
upon treatment with TNF in the presence of deacetylase inhibitors
(Fig. 1H, left and right panels). These results revealed that endogenous
PARP-1 was only acetylated in vivo upon stimulation in presence of
endogenous p300 or CBP (Fig. 1I).
PARP-1 Is Acetylated by p300/CBP in Vitro and in Vivo at Lys-498,
Lys-505, Lys-508, Lys-521, and Lys-524—Next, we tested whether
PARP-1 can be acetylated by p300 or CBP in vitro. Recombinant-puri-
fied full-length PARP-1 was incubated with recombinant-purified full-
length p300 or CBP in the presence of radioactive labeled acetyl-CoA
and resolved by SDS-PAGE followed by autoradiography analysis (Fig.
2A). PARP-1 was strongly acetylated in vitro by p300 or CBP (Fig. 2A).
To map the domains within PARP-1 subjected to acetylation by p300
and CBP, the same in vitro acetylation assay was repeated with different
PARP-1 fragments corresponding to amino acids 1–214, 215–372, 373–
525, 525–656, or 657–1014. These experiments revealed that p300 and
CBP strongly acetylated the PARP-1 domain corresponding to amino
acids 373–525 (Fig. 2B, left and right panels). Interestingly, a longer
autoradiography exposure revealed that the domain corresponding to
amino acids 1–214 of PARP-1 and to the small product of caspase
cleaved PARP-1, was weakly acetylated by p300 or CBP (supplemental
information and data not shown). The physiological relevance of this
finding is currently under investigation. To identify the lysines acety-
lated by p300/CBP within PARP-1, recombinant purified full-length
PARP-1 was acetylated in vitro by p300 full-length and analyzed by
microcapillary reverse-phase high performance liquid chromatography
nanoelectrospray tandem mass spectrometry. Lys-498, Lys-505, Lys-
508, Lys-521, andLys-524were identified as strong candidates for acety-
lation. To confirm that these lysines are the main acceptor sites, full-
length PARP-1 wild type or two PARP-1 mutant forms, mutKTR
(K498R/K521R/K524R) and mutKQR (K498R/K505R/K508R/K521R/
K524R) were incubated with p300 or CBP in the presence of radioactive
labeled acetyl-CoA and resolved by SDS-PAGE followed by autoradiog-
raphy analysis (Fig. 2C). These experiments confirmed that only the
PARP-1 mutant harboring all five mutated lysines was no longer acety-
lated in vitro by p300 and CBP (Fig. 2C). To investigate whether these
lysines are also themain acceptor sites for acetylation in vivo by p300,we
immunoprecipitated Myc-tagged PARP-1 wild type or mutant mut-
KQR under high salt conditions from nuclear extracts of 293 cells upon
treatment with the indicated stimuli in the presence or absence of
deacetylase inhibitors (Fig. 2D). The presence of acetylated forms of
PARP-1was tested by immunoblot analysis using an anti-AcK antibody.
PARP-1 was acetylated in vivo at Lys-498, Lys-505, Lys-508, Lys-521,
and Lys-524 in the presence of deacetylase inhibitors upon stimulation
(Fig. 2D, also see the supplemental information). The same experiments
performed in the presence of increasing amounts of overexpressed p300
suggested that these lysines are acetylated in vivo by p300 (Fig. 2E).
Acetylation of PARP-1 at Lys-498, Lys-505, Lys-508, Lys-521, and
Lys-524 Is Required in Vivo for Full NF-B-dependent Transcriptional
Activity—To directly test whether acetylation of PARP-1 is required for
NF-B-dependent transcriptional activity in vivo, we transfected PARP-
1(/) cells with expression vectors for p300 and PARP-1 wild type or
mutant mutKQR along with a luciferase reporter under the control of
the endogenous MIP-2 or iNOS promoters. Cells were subsequently
treated with the indicated stimuli (TNF or LPS/IFN) in the simulta-
neous presence or absence of low doses of deacetylase inhibitors (Fig. 3,
A and B). Coexpression of wild type p300 and wild type PARP-1 in
PARP-1(/) cells caused a highly synergistic enhancement of tran-
scription regulated from both MIP-2 and iNOS promoters upon stim-
ulation (Fig. 3, A and B). However, the cooperativity between p300 and
PARP-1 was severely impaired when the PARP-1 mutant mutKQR was
coexpressed. The most striking differences between PARP-1 wild type
and the mutant mutKQR were observed in the presence of low doses of
deacetylase inhibitors. The same transfection experiments with a
reporter gene under the control of mutated B sites revealed that the
observed induction was mainly NF-B-specific (Fig. 3, A and B; and
supplemental information).
Pavri et al. (32) have very recently shown that PARP-1 can associate in
vivo with the Mediator. Therefore, we repeated the same transfection
experiments in the presence of overexpressed subunits of the Mediator
complex. Coexpression of PARP-1 wild type, p300, and Mediator sub-
units inPARP-1(/) cells causedasynergisticenhancementofNF-B-
dependent transcription, whereas no synergistic enhancement was
observed when the mutant form of PARP-1, mutKQR, was coexpressed
(Fig. 3, C and D), indicating that acetylation of PARP-1 is also required
for the transcriptional cooperativity between p300/CBP, Mediator, and
PARP-1 on these promoters.
PARP-1 Interacts in Vivo with the Mediator Complex and in Vitro
Directly with the Mediator Subunits CDK8 and DRIP150—To further
confirm these data and to investigate whether CDK8 or other subunits
of the Mediator complex might directly interact with PARP-1, we first
coexpressed tagged forms of different Mediator subunits in 293 cells
(Fig. 4A). Immunoprecipitation experiments using an anti-PARP-1
antibody revealed that PARP-1 interacted with the whole Mediator
complex (Fig. 4A). Next, we repeated these experiments with primary
macrophages (Fig. 4B). These experiments revealed that endogenous
PARP-1 could indeed interact with the endogenous Mediator complex
under physiological conditions (Fig. 4B). DNAdid notmediate the asso-
ciation of PARP-1 with the Mediator in the nucleus since the presence
of ethidium bromide or DNase I did not affect PARP-1/Mediator inter-
action (data not shown). Surprisingly, whereas the interaction of
PARP-1 with the core Mediator module was increased upon stimula-
tion, the interaction of PARP-1 with CDK8 was decreased (Fig. 4,A and
B). CDK8 is thought to act mainly as a repressor sub-module of the
Mediator complex (32).
Because these results strongly suggested that PARP-1 would directly
interact with at least one of theseMediator subunits, recombinant puri-
fied GST-PARP-1 full-length was bound to glutathione beads followed
by incubation with in vitro translated and radioactive-labeled Mediator
PARP-1 Is Acetylated by p300/CBP
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subunits as indicated in Fig. 4C. After extensive washes, bound proteins
were resolved by SDS-PAGE followed by autoradiography analysis for
Mediator subunits. PARP-1 directly bound to CDK8 and MED14,
although to a low extent, but not to the other tested subunits (Fig. 4C).
We next tested whether PARP-1 might also directly interact with other
components of the RNA polymerase II machinery. Recombinant puri-
fied HMG(YI), CDK8, cyclin C, TFIIF/RAP74, TFIIF/RAP30, TATA
box-binding protein (TBP), and TBP-associated factors fused to GST
were bound to glutathione beads followed by incubation with recombi-
nant baculo-purified PARP-1 (Fig. 4D, left and right panels). After
extensivewashes, bound proteins were resolved by SDS-PAGE followed
by immunoblot analysis for PARP-1. PARP-1was able to bind directly to
HMG(YI), CDK8, and TFIIF/RAP74 but not to the other factors tested
(Fig. 4D, left and right panels).
Acetylation of PARP-1 at Lys-498, Lys-505, Lys-508, Lys-521, and
Lys-524 Stabilizes the Interaction of PARP-1 with p50—To investigate
whether acetylation of PARP-1 mechanistically influences protein-pro-
tein interactions, we first tested which of the interaction partners asso-
ciates with the acetylated domain of PARP-1. Different domains of
PARP-1 fused to GST were bound to glutathione beads and incubated
with purified p300, PARP-1, CDK8/cyclin C, p65, p50, TFIIF/RAP74 or
in vitro transcribed/translated and radioactive-labeledMED14 (Fig. 5,A
and B). After extensive washes, bound proteins were resolved by SDS-
PAGE followed by immunoblot analysis with the indicated antibodies
(Fig. 5A) or autoradiography (Fig. 5B). p300, PARP-1, CDK8, p65, p50,
TFIIF/RAP74, and MED14 bound to different domains of PARP-1 as
schematically drawn in Fig. 5C. PARP-1 interacted with a region
between amino acids 1 and 214 as well as between amino acids 465 and
FIGURE3.AcetylationofPARP-1 is required forNF-B-dependent transcriptionand for the transcriptional cooperativitybetweenPARP-1, p300/CBP, andMediator in vivo.
A and B, primary PARP-1(/) macrophageswere cotransfectedwith RSV-nt--Gal (300 ng), expression vectors for p300 (2g), and PARP-1wild type (WT) ormutantmutKQR (2g)
along with a luciferase reporter under the control of the endogenous MIP-2 (1 g) (A) or iNOS (3 g) (B) promoters; cells were subsequently treated for 4 h with TNF (10 ng/ml) or
LPS/IFN (0.05g/ml/100units) in the simultaneouspresenceor absenceof lowdoses of deacetylase inhibitors (10nMTSA/200MNAM). Cellswereharvested24hafter transfection,
and NF-B-dependent gene expression determined as described in Fig. 1C. C andD, primary PARP-1(/) macrophages were cotransfected with RSV-nt--Gal (300 ng), expression
vectors for p300 (2 g), MED-1 (2.5 g), MED-7 (0.4 g), MED-14 (2 g), MED-15 (1.1 g), MED-17 (0.75 g), MED-23 (1.5 g), MED-24 (1 g), and PARP-1 wild type or mutant
K498R/K505R/K508R/K521R/K524R ((mutKQR) (2 g) along with a luciferase reporter under the control of the endogenous MIP-2 (1 g) (C) or iNOS (3 g) (D) promoters; cells were
subsequently treated for 4 h with TNF (10 ng/ml) or LPS/IFN (0.05 g/ml/100 units) in the simultaneous presence of low doses of deacetylase inhibitors (HDi; 10 nM TSA/200 M
NAM). Cells were harvested 24 h after transfection and NF-B-dependent gene expression was determined as described in Fig. 1C.
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FIGURE 4. PARP-1 interacts with theMediator complex in vivo and directly with theMediator subunits MED14 and CDK8 in vitro. A, Myc- or FLAG-taggedMediator subunits
MED-1, MED-7, MED-14, MED-17, MED-23, and MED-24 were overexpressed in 293 cells and treated as indicated, and PARP-1 complexes were immunoprecipitated (IP) under
physiological salt conditions fromnuclear extracts usingananti-PARP-1 antibodyand tested for PARP-1 andMyc- or FLAG-taggedMediator subunits, p300, andCDK8by immunoblot
analysis using anti-PARP-1, anti-p300, anti-CDK8, anti-Myc, or anti-FLAG antibodies. C, control IgG; P1, anti-PARP-1. B, primary macrophages were treated as indicated with LPS (0.2
g/ml) for 1 h. PARP-1 was immunoprecipitated under physiological salt conditions from nuclear extracts, and the presence of Mediator subunits was subsequently tested by
immunoblot analysis using anti-MED1, anti-MED6 anti-TRAP150, anti-CDK8, or anti-PARP-1 antibodies. C, GST pull down assays under physiological salt conditions with PARP-1
full-length fused to GST (3 g GST fusion protein) and the indicated in vitro transcribed/translated Mediator subunits. Bound proteins were resolved by SDS-PAGE followed by
autoradiography. TheCoomassie control gel is shown in the left panel.D, GSTpull downassaysunderphysiological salt conditionswith the indicatedgeneral transcription factors and
CDK8/cyclin C fused to GST (1–4g of GST fusion protein) and baculo-purified PARP-1 (0.5g input). Bound proteins were resolved by SDS-PAGE followed by immunoblot analysis
using anti-PARP-1 antibodies (upper panel). The corresponding Coomassie control gel is shown in the lower panel. TBP, TATA box-binding protein.
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FIGURE5.AcetylationofPARP-1 stabilizes the interactionofPARP-1withp50butnotp65orPARP-1.A andB,mappingof the interactiondomains inPARP-1. ShownareGSTpull
down assays under high salt conditions with PARP-1 fragments fused to GST (1–3 g of protein) as indicated and recombinant purified p300 (2 g), PARP-1 (0.3 g), RAP74 (1 g),
CDK8 (1 g), cyclin C (0.5 g), p65 (0.5 g), and p50 (0.5 g) (A) or in vitro transcribed/translated MED14 (B). Bound proteins were resolved by SDS-PAGE followed by immunoblot
analysis with the corresponding antibodies (A) or autoradiography (B). The corresponding Coomassie control gel is shown in the lower panels. aa, amino acids. C, schematic picture
of the PARP-1 interactionmap: ZF I and ZFII, zinc finger 1 and 2;NLS, nuclear localization signal;HTH, helix turn helix domain, BRCT, C-terminal domain of a breast cancer susceptibility
protein (BRCA);WGR, central WGR motif-containing domain;PADR1, PARP regulatory domain; CC, catalytic center. D and E, acetylation-dependent interaction of PARP-1 and p50.
PARP-1 (D) or p50 (E) fused to GST (3 g/2 g) were incubated with in vitro acetylated or non-acetylated baculo-purified PARP-1 wild type (WT) or mutant formmutKQR (500 ng) in
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524 (Fig. 5C). MED14 was the only tested protein that bound to the
BRCT (carboxyl-terminal domain of a breast cancer susceptibility pro-
tein (BRCA)) domain of PARP-1. We have previously shown that p50
and p65 interact with a region between amino acids 341 and 531 of
PARP-1 (20). In addition, p50 interacted also with a region between
amino acids 1 and 140 containing the zinc finger I. Our more detailed
interaction analysis suggests that p65 would interact with a region
between amino acids 341 and 383 of PARP-1. p50 would interact with
zinc finger I or zinc finger II and with a region between amino acids 477
and 524 (Fig. 5C). Together, these experiments revealed that only the
interaction of PARP-1 with PARP-1 itself or p50might be influenced by
acetylation of PARP-1.
To test this hypothesis, recombinant purified PARP-1 or p50 fused to
GST were bound to glutathione beads and incubated with non-acety-
lated or in vitro acetylated purified PARP-1 wild type and the mutant
form mutKQR in the presence of increasing concentrations of NaCl as
indicated (Fig. 5,D and E). After extensive washes, bound proteins were
resolved by SDS-PAGE followed by immunoblot analysis for PARP-1
(Fig. 5, D and E). No significant differences between the acetylated or
non-acetylated form of PARP-1 were observed for the dimerization or
potential tetramerization of PARP-1 (Fig. 5D). Surprisingly, in vitro
acetylated PARP-1 bound significantly better to p50 than did the non-
acetylated PARP-1 (Fig. 5E). These results suggest that PARP-1 would
dimerize or potentially tetramerize through the regions between amino
acid 1 and 214 as well as between amino acid 465 and 497, whereas the
region between amino acid 477 and 524 is required for acetylation-de-
pendent interaction with p50 (Fig. 5C).
To confirm these in vitro data and to investigate whether acetylation
would influence the stimuli-dependent complex formation between
subunits of NF-B and PARP-1 in vivo, we coimmunoprecipitated the
NF-B subunits p65 and p50 from nuclear extracts upon treatment of
THP-1 with LPS in the presence or absence of deacetylase or phospha-
tase inhibitors (Fig. 5F, left and right panels) and tested the presence of
PARP-1 by immunoblot analysis using anti-PARP-1 antibodies.
Remarkably, PARP-1 bound significantly better to p65 when cells were
simultaneously treatedwith LPS and phosphatase inhibitors (Fig. 5F, left
panel), whereas p50 bound significantly better to PARP-1 upon simul-
taneous treatment with LPS and deacetylase inhibitors (Fig. 5F, right
panel). No significant differences between deacetylase or phosphatase
inhibitors were observed for the interaction between p50 and p65 (Fig.
5F, left and right panels). Taken together, these results suggest that
phosphorylation might mainly enhance the interaction between p65
and PARP-1, whereas acetylation mainly enhances the interaction
between p50 and PARP-1.
PARP-1 Interacts with Members of HDAC Class I and Is Potentially
Deacetylated by HDACs 1–3 in Vivo—Because acetylation of proteins is
known to be a reversible modification in vivo, we next tested whether
PARP-1 might physically interact with HDACs in vivo. Because of the
low quality of commercially available anti-HDAC antibodies, we
decided to perform these experiments with overexpressed Myc- or
FLAG-tagged HDACs. We coimmunoprecipitated PARP-1 complexes
from nuclear extracts of untreated 293 cells overexpressingMyc-tagged
versions of HDAC-1, HDAC-2, or HDAC-3 (Fig. 6A) and FLAG-tagged
versions of HDAC-4, HDAC-5 or HDAC-6 (Fig. 6B) and tested the
FIGURE 5—continued
presence of increasing concentrations of NaCl (125 mM NaCl, 25 mM potassium acetate to 225 mM NaCl, 25 mM potassium acetate) as indicated. Bound proteins were resolved by
SDS-PAGE followed by immunoblot analysis using a anti-PARP-1 antibody. F, acetylation and stimuli-dependent complex formation of PARP-1 and subunits of NF-B in vivo. NF-B
subunits p65 and p50were coimmunoprecipitated (IP) from nuclear extracts upon treatment of THP-1 with LPS in the presence or absence of deacetylase or phosphatase inhibitors
(left and right panels) and tested for the presence of p50, p65, and PARP-1 by immunoblot analysis using anti-p50, anti-p65, and anti-PARP-1 antibodies. C, control.
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FIGURE 6. PARP-1 interacts with members of HDAC class I and is potentially deacetylated by HDAC-1, HDAC-2, or HDAC-3 in vivo. A and B, FLAG-tagged HDACs were
overexpressed in 293 cells. PARP-1 complexes were co-immunoprecipitated (IP) from nuclear extracts of untreated 293 cells using an anti-PARP-1 (P1) antibody and subsequently
tested for PARP-1 and Myc-tagged HDAC-1, HDAC-2, or HDAC-3 and FLAG-tagged HDAC-4, HDAC-5, or HDAC-6 by immunoblot (WB) analysis using anti-PARP-1, anti-Myc or
anti-FLAGantibodies. c, control IgG.C, GSTpull downassaysunderphysiological salt conditionswithPARP-1 fused toGST (4gofprotein) and in vitro transcribed/translatedHDAC-1,
-2, -3, or -8. Bound proteins were resolved by SDS-PAGE followed by autoradiography (left panel). The corresponding Coomassie control gel is shown in the right panel. D and E,
FLAG-tagged PARP-1 wild type was coexpressed with increasing amounts of Myc-tagged HDAC-1, HDAC-2, or HDAC-3 and hemagglutinin (HA)-tagged HDAC-4 or HDAC-5 in 293
cells. 24 h later cells were simultaneously treated with TNF (10 ng/ml) and NAM (1 mM) for 30 min. FLAG-tagged PARP-1 was subsequently immunoprecipitated under high salt
conditions from nuclear extracts of 293 cells, and the presence of acetylated forms of PARP-1 was tested by immunoblot analysis using anti-AcK or anti-FLAG antibodies.
PARP-1 Is Acetylated by p300/CBP
40460 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 280•NUMBER 49•DECEMBER 9, 2005
FIGURE 7. The coactivator activity of PARP-1 is negatively regulated in vivo byHDAC-1 HDAC-2, or HDAC-3. A–F, primary PARP-1(/) macrophages were cotransfectedwith
expression vectors for RSV-nt--Gal (300 ng), PARP-1wild type (WT) ormutantmutKQR (2g), p300 (2g), HDAC-1, HDAC-2, or HDAC-3 (2.5g each) alongwith a luciferase reporter
under the control of the endogenous MIP-2 (1 g) (A–C) or iNOS promoters (3 g) (D–F); cells were subsequently treated for 4 h with TNF (10 ng/ml) or LPS/IFN (0.05 g/ml/100
units) in the simultaneous presence of low doses of deacetylase inhibitor (500 M NAM). Cells were harvested 24 h after transfection, and NF-B-dependent gene expression was
determined as described in Fig. 1C.
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presence of these HDACs by immunoblot analysis using anti-PARP-1,
anti-Myc, or anti-FLAG antibodies. Interestingly, PARP-1 interacted
with HDAC-1, HDAC-2, and HDAC-3 but not with HDAC-4,
HDAC-5, or HDAC-6 (Fig. 6, A and B). DNA did not mediate the asso-
ciation of PARP-1 withHDACs since the presence of ethidium bromide
orDNase I did not affect the interaction (data not shown). Because these
results suggested that PARP-1 would directly interact with at least one
of these HDACs, GST-PARP-1 full-length was bound to glutathione
beads and incubated with in vitro translated and radioactive-labeled
HDAC class ImembersHDAC-1, HDAC-2, HDAC-3, orHDAC-8 (Fig.
6C). After extensive washes, bound proteins were resolved by SDS-
PAGE followed by autoradiography analysis forHDACs. PARP-1 bound
directly to HDAC-1, HDAC-2, and HDAC-3 but not to HDAC-8
(Fig. 6C).
To investigate whether PARP-1 might be deacetylated by HDAC-1,
HDAC-2, or HDAC-3 in vivo, FLAG-tagged PARP-1 wild type was
coexpressed with increasing amounts of Myc-tagged HDAC-1,
HDAC-2, or HDAC-3 (Fig. 6D) and hemagglutinin-tagged HDAC-4 or
HDAC-5 in 293 cells (Fig. 6E). FLAG-tagged PARP-1 was immunopre-
cipitated from nuclear extracts under high salt conditions upon treat-
ment of cells with TNF andNAM. The presence of acetylated forms of
PARP-1 was tested by immunoblot analysis using anti-AcK or anti-
FLAG antibodies. These experiments revealed that PARP-1 might be
deacetylated in vivo byHDAC-1,HDAC-2, orHDAC-3 (Fig. 6,D andE).
PARP-1-dependent Transcriptional Activation of NF-B Seems to Be
Negatively Regulated by HDACs 1–3 in Vivo—Next, we tested which
HDAChas the strongest influence on the transcriptional coactivator activ-
ity of PARP-1 andmight therefore also act functionally as a deacetylase for
PARP-1 in vivo. PARP-1(/) cells were cotransfected with expression
vectors for PARP-1 wild type or PARP-1 mutant form; that is, mutKQR,
p300, HDAC-1, HDAC-2, or HDAC-3 along with a luciferase reporter
under the control of the endogenousMIP-2 (Fig. 7,A–C) or iNOSpromot-
ers (Fig. 7,D–F). Cellswere simultaneously treatedwith the indicated stim-
uli (TNF or LPS/IFN) and low doses of deacetylase inhibitors (Fig. 7,
A–F). Coexpression of p300 with HDAC-1, HDAC-2, or HDAC-3 in the
absence of PARP-1 resulted in a reduced activation of NF-B-dependent
transcriptional activation (Fig. 7, A–F). No significant differences between
HDAC-1, HDAC-2, or HDAC-3 were observed in the absence of PARP-1
for eitherMIP-2 or iNOSpromoters (Fig. 7,A–F), indicating that the resid-
ual activation of NF-B in PARP-1(/) cells in the absence of PARP-1 is
equally repressed byHDAC-1, HDAC-2, or HDAC-3. Similar results were
obtained in presence of PARP-1 wild type, although the repression by
HDAC-2was weaker when comparedwithHDAC-1 andHDAC-3 (Fig. 7,
A–F). Remarkably, the repression by HDAC-1, HDAC-2, or HDAC-3 was
strongly reduced when HDAC-1 HDAC-2, or HDAC-3 was coexpressed
withPARP-1mutantmutKQR (Fig. 7,A–F). Together these results suggest
that HDAC-1, HDAC-2, and HDAC-3 might repress NF-B-dependent
transcription in part through deacetylation of PARP-1.
DISCUSSION
Growing experimental evidence suggests that PARP-1 can function
as a promoter-specific coactivator (17). PARP-1was also identified as an
interaction partner not only of NF-B but also of several sequence-
specific transcription factors and cofactors including E2F1, Oct-1, and
PC3/topoisomerase-I (17, 33) and has been shown to increase the tran-
scriptional activity of these transcription factors (17). In 1997 Meister-
ernst et al. (34) identified human PARP-1 as one active component of
the upstream stimulatory activity (USA)-derived positive cofactor com-
plex PC-1 (34). The crude precursor human USA fraction consists of
PC1/PARP-1, PC2/Mediator-like complex, PC3/topoisomerase-I, PC4/
single-stranded DNA-binding protein, PC52, PC6, and HMG2 (34, 35).
Earlier studies showed that full activation of transcription by NF-B,
Sp1, and Oct-1 in cell-free systems required a crude precursor USA
coactivator fraction in addition to general transcription factors (36).
Because PC1/PARP-1, PC3, and PC4 are all sequence-unspecific DNA-
binding proteins, it was suggested that PC1/PARP-1 provide together
with the other USA-derived positive cofactors PC3, PC4, PC52, and
HMG2 a mainly structural/architectural role in assembling and stabi-
lizing the pre-initiation complex by affecting the accessibility of RNA
polymerase II to chromatin (17, 34, 35, 37).
The aim of this study was to investigate whether the coactivator activity
of PARP-1 might be regulated by post-translational modifications such as
acetylation. We provide both biochemical and functional evidence that
acetylation of PARP-1 is required for its NF-B coactivator activity.
PARP-1 Requires the Enzymatic Activity of p300 for Full NF-B-
dependent Transcriptional Activity—Several reports demonstrated that
coactivator activity of PARP-1 for NF-B-dependent gene expression
seems to be dependent on the stimuli and cell type (17).We observed an
impaired expression in primary PARP-1(/) macrophages of iNOS,
KC, and MIP-2 genes but not of IB and IL-6 upon stimulation with
TNF or LPS/IFN, indicating that PARP-1 acts in a promoter-specific
manner, similar to other coactivators of NF-B such as CARM1 (16).
PARP-1 and p300/CBP were shown to form a complex and function
synergistically to enhance NF-B-mediated gene expression (8). More-
over, we recently provided evidence that the enzymatic activities of
p300/CBP and protein argininemethyltransferase CARM1 are required
for NF-B-dependent gene expression in vivo (16). NF-B-dependent
reporter gene analysis using the PARP-1-dependent MIP-2 and iNOS
promoters revealed that the cooperativity between p300 and PARP-1
was severely impaired when an enzymatic mutant of p300 was coex-
pressed, indicating that the enzymatic activity of p300/CBP is required
for NF-B-dependent transactivation of PARP-1-dependent promoters
upon treatment with inflammatory stimuli.
PARP-1 Is Acetylated in Vivo at Lys-498, Lys-505, Lys-508, Lys-521,
and Lys-524 by p300/CBP upon Stimulation—Growing experimental
evidence has accumulated that NF-B-dependent gene expression is
also regulated by post-translational modifications such acetylation (22).
This acetylation-dependent regulation was shown to occur at multiple
levels (38). Acetylation of histones regulates theNF-B-dependent gene
accessibility (22). Moreover, direct acetylation of the NF-B subunits
p65 and p50 was shown to regulate transcriptional activation of NF-B
(39–41). Finally, other acetylation eventswere suggested to temporarily
modulate the duration of NF-B presence in the nucleus and DNA
binding activity as well as protein-protein interactions with several
cofactors involved in the transcriptional activity of NF-B (22, 38). It
was recently reported that the USA-derived positive cofactor PC4 is
specifically acetylated by p300, thereby stimulating its double-stranded
DNA binding activity which correlates with its coactivation activity (42,
43). Here we show that PARP-1 is acetylated in vitro and in vivo by p300
and CBP. Combined analysis by microcapillary reverse-phase high per-
formance liquid chromatography nanoelectrospray tandemmass spec-
trometry and coexpression of p300/CBP and PARP-1 wild type or
mutant revealed that PARP-1 is acetylated in vivo at Lys-498, Lys-505,
Lys-508, Lys-521, and Lys-524 by p300/CBP upon stimulation. In vitro
acetylation experiments using purified recombinant PARP-1 wild type
or mutant forms supported these in vivo observations.
Acetylation of PARP-1 at Lys-498, Lys-505, Lys-508, Lys-521, and
Lys-524 Is Required for NF-B-dependent Transcriptional Activity in
Vivo—The importance of PARP-1 acetylation for NF-B-dependent tran-
scription is supported by complementation experiments in primary PARP-
PARP-1 Is Acetylated by p300/CBP
40462 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 280•NUMBER 49•DECEMBER 9, 2005
1(/)macrophages using the PARP-1mutantmutKQR (K498R/K505R/
K508R/K521R/K524R). Full synergistic enhancement of transcription
regulated from the MIP-2 and iNOS promoters was obtained only when
PARP-1 wild type was coexpressed with p300 in PARP-1(/) macro-
phages. The observed residual cooperative effects in the presence of
mutatedBsites on thepromotermost likely reflect the coactivator activity
of PARP-1 on other sequence-specific transcription factors such as activa-
tor protein-1, Sp-1,Oct-1, interferon regulatory factors, or signal transduc-
ers and activators of transcription (STATs), which are also important for
full activity of NF-B on these promoters (24, 44–46). Several recent
reports provided evidence that PARP-1 might also act as a coactivator of
AP-1 and STATs (47–49). Interestingly, the observed differences between
PARP-1 wild type and mutant mutKQR regarding the co-operativity of
p300 and PARP-1 were less significant in experiments using reporter plas-
midswithmutatedBsites, suggesting that acetylationofPARP-1mightbe
mainly required for the NF-B-dependent promoter activity. However, it
remains to be further investigated whether acetylation of PARP-1 could
also strongly influence other sequence-specific transcription factors or
cofactors under certain conditions. Remarkably, coexpression of PARP-1
wild type or mutant mutKQR with p300 andMediator subunits in PARP-
1(/) macrophages demonstrated that acetylation of PARP-1 is also
required for the transcriptional cooperativity between p300/CBP, Media-
tor, and PARP-1 on these promoters. Recent reports showed that ARC/
Mediator interacts with the transactivation domain of p65 and enhances
chromatin-dependent transcriptional activation by p65 in vitro (50). The
Mediator complex is thought to provide the penultimate step in the activa-
tion process by bridging a given activator to RNA polymerase II and form-
ing a scaffold onto which RNA polymerase II and general transcription
factors can assemble and initiate transcription (51). Based on themultistep
interaction model of transcriptional activation proposed by Roeder and
co-workers (51), it was suggested that PC1/PARP-1 might facilitate
togetherwith other structural/architectural positive cofactors the co-oper-
ative interactions between sequence-specific activators and different coac-
tivator complexes such as p300/CBP and Mediator, thereby providing an
architectural function in stabilizing the pre-initiation complex (17). In our
current studiesweprovidedevidence thatPARP-1 interacts in vivowith the
Mediator complex under physiological conditions. Furthermore, PARP-1
directly interacted in vitrowith the Mediator subunits MED14 and CDK8
aswell as theTFIIF subunit RAP74but notwithTFIIB,TATAbox-binding
protein (TBP) and the testedTBP-associated factors.These results are con-
sistent with the observation ofMeisterernst et al. (34) that in “in vitro tran-
scription” assays, PARP-1 is only required during assembly of RNApolym-
erase II andgeneral transcription factorsonpreformedTFIID-TFIIA-DNA
complexes (34). In these studies PARP-1 was unable to stimulate the for-
mation of a TFIID-promoter complex. In addition, PARP-1 stimulated
transcription only when added before the complete pre-initiation complex
was formed,which implies that PARP-1might only functionduring assem-
bly of the pre-initiation complex (34).
Whether acetylation of PARP-1 might regulate the PARP-1 activity at
this level in the context of chromatin remains to be investigated. However,
it seems unlikely since theMediator subunits DRIP150 and CDK8 did not
bind to the acetylated domain in PARP-1. Surprisingly, acetylation of
PARP-1 regulates the stimuli-dependent interaction of PARP-1 with
NF-B1 subunit p50 but not p65. Because the acetylationmutantmutKQR
of PARP-1 could still partially coactivate NF-B, acetylation of PARP-1
might be mechanistically required for the stabilization of preformed
PARP-1 containing transcriptional coactivator-cofactor complexes.
PARP-1-dependent Transcriptional Activation of NF-B Seems to Be
Negatively Regulated in Vivo by HDACs 1–3—Overexpression of
HDAC-1, HDAC-2, and HDAC-3 was shown to repress NF-B-de-
pendent transcription upon treatment with inflammatory stimuli (22,
38, 41). HDAC-3 was shown to be required for the deacetylation of p65
(52). HDAC-1, HDAC-2, and HDAC-3 interact directly with several
proteins involved in the NF-B signaling pathway, including NF-B
itself (22, 52, 53). Interestingly, PARP-1 formed a complex with
HDAC-1, HDAC-2, or HDAC-3 in the nucleus but not with HDAC-4,
HDAC-5, or HDAC-6. The direct interaction in vitro between PARP-1
and HDACs 1–3 was weak and might be very transient or regulated in
vivo by other unidentified post-translational modifications. Subsequent
in vivo deacetylation experiments with increasing amounts of overex-
pressed HDACs suggested that deacetylation of PARP-1 in vivo might
be mediated by HDAC-1, HDAC-2, or HDAC-3. Transient reporter
assays revealed that the PARP-1-dependent transcriptional activity of
NF-B is negatively regulated in vivo by HDAC-1, HDAC-2, or
HDAC-3. Because transiently transfected plasmids seemnot to be prop-
erly chromatinized, nucleosomal histones are unlikely to represent the
only relevant substrates whose lysine acetylation is required for NF-B-
dependent transcription. Remarkably, when HDAC-1, HDAC-2, or
HDAC-3 was co-expressed with PARP-1 mutant mutKQR, no signifi-
cant additional promoter-specific decrease in NF-B-dependent tran-
scription was obtained. These results suggest that HDAC-1, HDAC-2,
and HDAC-3might deacetylate promoter-bound PARP-1 or other uni-
dentified cofactors or coactivators dependent on acetylation of PARP-1.
Interestingly, several recent reports demonstrated that inhibition of
HDACs could selectively suppress transcription in a gene-specific manner
by inducing an elongational arrest and/or premature termination between
exons 1 and 2 (54–57). Thus, in the context of chromatin, it might be that
for at least a subset of NF-B-dependent genes, deacetylation of NF-B
itself or of coactivators involved in the nuclear activity of NF-B, such as
PARP-1, could be required for transcriptional elongation or re-initiation.
For at least a subset of PARP-1-dependent NF-B target genes, both the
enzymatic activities of p300 and acetylation of PARP-1 are required for
transcriptional activity. However, the exact molecular mechanism by
which acetylationofPARP-1 regulates the coactivator activity of PARP-1 in
the context of chromatin remains to be investigated. In addition,we cannot
exclude the possibility that other histone acetyltransferasesmight acetylate
PARP-1 on other lysine residues and thereby influence its activities.
Whether p65 or other sequence-specific transcription factors known to
cooperate with NF-B in gene induction could regulate the acetylation of
PARP-1 is currently under investigation.
Taken together, these results support the hypothesis that the differ-
ent physiological functions of PARP-1 are regulated by post-transla-
tional modifications such as acetylation in a stimuli-specific manner.
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